This study evaluates the efficacity of Erickson hypnosis in the treatment of chronic pain in patients with Parkinson's disease. Half of participants will follow a 2-month Erickson hypnosis protocole, while the other half will benefit from the usual care.
A large proportion of patients with Parkinson's disease suffer of chronic pain directly related to the disease. The management of painful symptoms is difficult and currently, there is no commonly admitted guidelines. Several studies have shown the efficacy of Erickson hypnosis to reduce the perception of chronic pain in different conditions. This efficacy has never been tested in Parkinson's disease. The objective of this study is to assess the efficacy of Erickson hypnosis protocol, compared to usual care, for the management of Parkinson's disease-related chronic pain. The study team assume that Erickson hypnosis will be more efficient than usual care to reduce perceived chronic pain. They also assume that regular practice of autohypnosis will contribute to long-term efficacy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
33
Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
Chu Cote de Nacre
Caen, France
Hôpital Roger Salengro, CHRU de Lille
Lille, France
Hopital Charles Nicolle Chu Rouen
Rouen, France
Hopital Purpan Chu Toulouse
Toulouse, France
Change of the intensity of pain perception
Measure of the intensity of pain perception by VAS at the baseline visit and at the post-treatment visit (2 months later). The difference between both values will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at the Brief Pain Inventory
Completion of the Brief Pain Inventory at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at the McGill Pain Questionnaire
Completion of the McGill Pain Questionnaire at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at the Beck Depression Inventory
Completion of the Beck Depression Inventory at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at the Fatigue Severity Scale
Completion of the Fatigue Severity Scale at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at the Parkinson's Disease Questionnaire-8 (PDQ-8)
Completion of the PDQ-8 at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At baseline and 2 months after
Change of the score at the Scale for Outcomes at Parkinson's Disease (SCOPA-PS)
Completion of the SCOPA-PS at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at the Euroqol 5 dimensions 5 levels (EQ-5D-5L)
Completion of the EQ-5D-5L at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change in the dose of analgesic treatments
Analgesic treatments will be recorded during the week preceding each visit and a mean dosage will be calculated during each period. The difference between both mean values will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change in the dose of psychotropic medications
Psychotropic medications will be recorded during the week preceding each visit and a mean dosage will be calculated during each period. The difference between both mean values will allow to calculate a variation index.
Time frame: At baseline and 2 months after
Change of the score at MDS-UPDRS
Completion of the MDS-UPDRS at the baseline visit and at the post-treatment visit (2 months later). The difference between both scores will allow to calculate a variation index.
Time frame: At baseline and 2 months after